All In Biotech

Drug Trial Radar · NCT04322539

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 691 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

691

Actual

Start

Aug 12, 2020

Primary completion

Jul 29, 2022

Study completion Apr 24, 2024

Sponsor

Lead sponsor
Hutchison Medipharma LimitedIndustry
Sponsor type
Industry
First posted
Mar 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were randomized to one of the following treatment arms in a 2:1 ratio, fruquintinib plus BSC or placebo plus BSC.

Conditions

  • Metastatic Colorectal Cancer
  • Metastatic Colon Cancer

Interventions

  • FruquintinibDrug

    Oral VEGFR inhibitor

  • PlaceboDrug

    Placebo capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From date of randomization to death from any cause (up to 22 months)

Locations

153 sites in 14 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Arizona Oncology Associates, PC-HOPE

    Tucson, Arizona

  • California Research Institute (CRI)

    Los Angeles, California

  • City of Hope Comprehensive Cancer Center

    Los Angeles, California

  • Rocky Mountain Cancer Center

    Aurora, Colorado

  • The George Washington University Medical Center

    Washington D.C., District of Columbia

  • Sarah Cannon Research Institute-S-Ft. Myers (FCS South)

    Fort Myers, Florida

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • Cancer Care Centers of Brevard, Inc.

    Palm Bay, Florida

  • Sarah Cannon Research Institute-N-St Pete (FCS North)

    St. Petersburg, Florida

  • Sarah Cannon Research Institute-Pan-Tallahassee (FCS Panhandle)

    Tallahassee, Florida

  • Sarah Cannon Research-E-WPB (Florida Cancer Specialists-FCS East)

    West Palm Beach, Florida

  • Emory Winship Cancer Institute

    Atlanta, Georgia

  • Illinois Cancer Specialists

    Arlington Heights, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • Affiliated Oncologists

    Chicago Ridge, Illinois

  • XCancer / Central Care Cancer Center

    Garden City, Kansas

  • University of Louisville - James Brown Cancer Center

    Louisville, Kentucky

  • Norton Cancer Institute Audubon

    Louisville, Kentucky

  • Hematology Oncology Clinic

    Baton Rouge, Louisiana

  • XCancer / Pontchartrain Cancer Center

    Hammond, Louisiana

  • Maryland Oncology Hematology, P.A.

    Columbia, Maryland

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Minnesota Oncology

    Minneapolis, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Center for Pharmaceutical Research

    Kansas City, Missouri

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • XCancer / New Mexico Oncology & Hematology Consultants

    Albuquerque, New Mexico

  • Charleston Oncology

    Charleston, South Carolina

  • Sarah Cannon Tennessee Oncology

    Nashville, Tennessee

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee

  • Texas Oncology - Austin

    Austin, Texas

  • Texas Oncology Baylor Sammons

    Dallas, Texas

  • Texas Oncology-El Paso

    El Paso, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology-McAllen

    McAllen, Texas

  • Texas Oncology-San Antonio

    San Antonio, Texas

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.